Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: Results of the Dutch Multicentre EPS Study

Nephrology Dialysis Transplantation

Volumn 26, Issue 2, 2011, Pages 691-697

  Korte, Mario R ^a,b   Fieren, Marien W ^b   Sampimon, Denise E ^c   Lingsma, Hester F ^b   Weimar, Willem ^b   Betjes, Michiel G H ^b  

^a ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

encapsulating peritoneal sclerosis; peritoneal dialysis; survival; tamoxifen

Indexed keywords

AZATHIOPRINE; PREDNISONE; TAMOXIFEN;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); PARENTERAL NUTRITION; PERITONEAL FIBROSIS; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 79551487598     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq362     Document Type: Article

References (51)

1. Chin AI, Yeun JY. Encapsulating peritoneal sclerosis: An unpredictable and devastating complication of peritoneal dialysis. Am J Kidney Dis 2006; 47: 697-712
2. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13: 154-159
3. Garosi G, Di Paolo N, Sacchi G et al. Sclerosing peritonitis: a nosological entity. Perit Dial Int 2005; 25: S110-S112
4. Kawaguchi Y, Saito A, Kawanishi H et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005; 25: S83-S95
5. Nakamoto H. Encapsulating peritoneal sclerosis-a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005; 25: S30-S38
6. Tarzi RM, Lim A, Moser S et al. Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. Clin J Am Soc Nephrol 2008; 3: 1702-1710
7. de Freitas D, Jordaan A, Williams R et al. Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. Perit Dial Int 2008; 28: 271-276
8. Kawanishi H, Watanabe H, Moriishi M et al. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25: S39-S47 (Pubitemid 41600358)
9. Kawanishi H, Kawaguchi Y, Fukui H et al. Encapsulating peritoneal sclerosis in japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44: 729-737
10. Junor BJ, McMillan MA. Immunosuppression in sclerosing peritonitis. Adv Perit Dial 1993; 9: 187-189
11. Lafrance JP, Letourneau I, Ouimet D et al. Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis 2008; 51: e7-e10
12. Eltoum MA, Wright S, Atchley J et al. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 2006; 26: 203-206
13. Park WC, Jordan VC. Selective estrogen receptor modulators (SERMs) and their roles in breast cancer prevention. Trends Mol Med 2002; 8: 82-88
14. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project p-1 study. J Natl Cancer Inst 1998; 90: 1371-1388
15. Fisher B, Costantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479-484 (Pubitemid 19062522)
16. Adjuvant tamoxifen in the management of operable breast cancer. The Scottish trial. Report from the breast cancer trials committee, Scottish cancer trials office (MRC), Edinburgh. Lancet 1987; 2: 171-175
17. van Bommel EF, Hendriksz TR, Huiskes AWet al. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 2006; 144: 101-106
18. Pritchyk K, Newkirk K, Garlich P et al. Tamoxifen therapy for Riedel's thyroiditis. Laryngoscope 2004; 114: 1758-1760
19. Balasubramaniam G, Brown EA, Davenport A et al. The panthames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2009; 24: 3209-3215
20. Gupta S, Woodrow G. Successful treatment of fulminant encapsulating peritoneal sclerosis following fungal peritonitis with tamoxifen. Clin Nephrol 2007; 68: 125-129
21. Betjes MGH, Sampimon D, Lingsma H et al. Risk factors associated with increased incidence of encapsulating peritoneal sclerosis in a controlled multicenter study. J Am Soc Nephrol 2009 Abstract issue: 553776
22. Korte MR, Yo M, Betjes MG et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant 2007; 22: 2412-2414
23. Kawaguchi Y, Kawanishi H, Mujais S et al. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20: S43-S55
24. Kuriyama S, Tomonari H. Corticosteroid therapy in encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2001; 16: 1304-1305
25. Mori Y, Matsuo S, Sutoh H et al. A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 1997; 30: 275-278
26. Dejagere T, Evenepoel P, Claes K et al. Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient. Am J Kidney Dis 2005; 45: e33-e37
27. Fagugli RM, Selvi A, Quintaliani G et al. Immunosuppressive treatment for sclerosing peritonitis. Nephrol Dial Transplant 1999; 14: 1343-1345
28. Wong CF, Beshir S, Khalil A et al. Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit Dial Int 2005; 25: 285-287
29. Rajani R, Smyth J, Koffman CG et al. Differential effect of sirolimus vs prednisolone in the treatment of sclerosing encapsulating peritonitis. Nephrol Dial Transplant 2002; 17: 2278-2280
30. Fieren MW, Betjes MG, Korte MR et al. Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 2007; 27: 619-624
31. Allaria PM, Giangrande A, Gandini E et al. Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? J Nephrol 1999; 12: 395-397
32. Pollock CA. Bloody ascites in a patient after transfer from peritoneal dialysis to hemodialysis. Semin Dial 2003; 16: 406-410
33. Evrenkaya TR, Atasoyu EM, Unver S et al. Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2004; 19: 2423-2424
34. Moustafellos P, Hadjianastassiou V, Roy D et al. Tamoxifen therapy in encapsulating sclerosing peritonitis in patients after kidney transplantation. Transplant Proc 2006; 38: 2913-2914
35. Thirunavukarasu T, Saxena R, Anijeet H et al. Encapsulating peritoneal sclerosis presenting with recurrent ascites and tamoxifen: case reports and review of the literature. Ren Fail 2007; 29: 775-776
36. Dogan E UH, Sayarlioglu H, Sahin M et al. Sclerosing encapsulating peritonitis in an anti-HCV positive patient on chronic ambulatory peritoneal dialysis. Ren Fail 2007; 29: 777-778
37. Mesquita M, Guillaume MP, Dratwa M. First use of tamoxifen in an HIV patient with encapsulating peritoneal sclerosis. Clin Drug Investig 2007; 27: 727-729
38. Korzets A, Ori Y, Zevin D et al. A worrying thought-could there be a connection between encapsulating peritoneal sclerosis, tamoxifen and calciphylaxis? Nephrol Dial Transplant 2006; 21: 2975-2978
39. del Peso G, Bajo MA, Gil F et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003; 19: 32-35
40. Turner MW HJ. Successful therapy of sclerosing peritonitis. Semin Dial 1992; 5: 316
41. Selgas R, Bajo A, Jimenez-Heffernan JA et al. Epithelial-tomesenchymal transition of the mesothelial cell-its role in the response of the peritoneum to dialysis. Nephrol Dial Transplant 2006; 21: ii2-ii7
42. Yanez-Mo M, Lara-Pezzi E, Selgas R et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348: 403-413 (Pubitemid 36159357)
43. Margetts PJ, Bonniaud P, Liu L et al. Transient overexpression of tgf- {beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005; 16: 425-436
44. Zweers MM, deWaart DR, Smit Wet al. Growth factors vegf and tgfbeta1 in peritoneal dialysis. J Lab Clin Med 1999; 134: 124-132
45. Io H, Hamada C, Ro Yet al. Morphologic changes of peritoneum and expression of vegf in encapsulated peritoneal sclerosis rat models. Kidney Int 2004; 65: 1927-1936
46. Yoshio Y, Miyazaki M, Abe K et al. Tnp-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 2004; 66: 1677-1685
47. Tanabe K, Maeshima Y, Ichinose K et al. Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney Int 2007; 71: 227-238
48. Kuhn MA, Wang X, Payne WG et al. Tamoxifen decreases fibroblast function and downregulates tgf(beta2) in dupuytren's affected palmar fascia. J Surg Res 2002; 103: 146-152
49. Garvin S, Dabrosin C. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 2003; 63: 8742-8748 (Pubitemid 38064052)
50. McNamara DA, Harmey J, Wang JH et al. Tamoxifen inhibits endothelial cell proliferation and attenuates vegf-mediated angiogenesis and migration in vivo. Eur J Surg Oncol 2001; 27: 714-718
51. Topley N. Encapsulating peritoneal sclerosis: time to act. Perit Dial Int 2006; 26: 564-565